Latest Breaking News On - ஐரோப்பிய சங்கம் ஆஃப் சிறுநீரகம் - Page 3 : comparemela.com
Testosterone Therapy for Hypogonadism May Cut Risk for CV Events
renalandurologynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from renalandurologynews.com Daily Mail and Mail on Sunday newspapers.
EAU 2021: ctDNA Guiding Adjuvant Immunotherapy in Urothelial Carcinoma
urotoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from urotoday.com Daily Mail and Mail on Sunday newspapers.
Testosterone Therapy for Hypogonadism May Cut Risk for CV Events
physiciansweekly.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from physiciansweekly.com Daily Mail and Mail on Sunday newspapers.
Testosterone Therapy for Hypogonadism May Cut Risk for CV Events
empr.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from empr.com Daily Mail and Mail on Sunday newspapers.
3 IMvigor 210
First-line maintenance treatment: JAVELIN Bladder 100
5
Given the above success of immunotherapy in bladder cancer, there is great interest in the possibility of moving immunotherapy into the neoadjuvant disease space. Currently, there are many ongoing clinical trials for neoadjuvant immunotherapy:
6
7 and ABACUS
8 phase II trials. PURE-01 enrolled 143 patients that were treated with 3 cycles of pembrolizumab, resulting in a pT0 rate of 37%. ABACUS enrolled 95 patients that were treated with two cycles of atezolizumab, resulting in a pT0 rate of 31%. Three clinical trials have assessed the utility of immunotherapy combination therapy, including the NABUCCO (ipilimumab + nivolumab x 3), DUTRENEO (durvalumab + tremelimumab x 3), and durvalumab + tremelimumab x 2 (NCT02812420). As follows is a summary of these trials: